Valeant Pharma (VRX) Gains Early on Renewed Chatter

September 21, 2016 10:00 AM EDT

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Valeant Pharma (NYSE: VRX) is gaining early on reoccurring rumors the company has a bid for its Bausch & Lomb unit.

While originally saying it won't sell core assets like Bausch & Lomb, CEO Joe Papa recently softened his stance saying he'll 'never say never' on core assets sales.

Shares of VRX are up 1.25% early.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Rumors

Add Your Comment